Biosimilars aim to be lower cost options for biologic therapies after loss of exclusivity. A key question is whether these cost savings get passed through to patients via lower out-of-pocket costs. A paper by Dayer et al. (2026) aims to answer this question using 2011-2023 Merative MarketScan Commercial claims data. The authors observed:
…significant patient OOP savings because of biosimilar competition, with an average annual OOP difference of −$1,133.90 (95% CI −$1,200.35 to −$1,067.45) in the infliximab group, −$1,437.63 (95% CI −$1,549.98 to −$1,325.28) in the rituximab group, and −$375.01 (95% CI −$539.57 to −$210.45) in the adalimumab group compared with the control group during the study period…
The availability of infliximab and rituximab biosimilars has led to significant savings for patients, with savings increasing the longer biosimilars remain on the market.
You can read the full article here.
